ストックスクリーナーアプリを入手
2.05
1.49%
0.03
アフターアワーズ：
2.05
前日終値:
$2.02
開ける：
$2.01
24時間の取引高:
389.79K
Relative Volume:
0.25
時価総額：
$117.78M
収益：
$70.00M
当期純損益:
$-43.21M
株価収益率:
-2.7048
EPS:
-0.7579
ネットキャッシュフロー:
$-34.03M
1週間 パフォーマンス:
+3.54%
1か月 パフォーマンス:
+14.53%
6か月 パフォーマンス:
-8.07%
1年 パフォーマンス:
-25.72%
1日の値動き範囲:
$2.01
$2.085
1週間の範囲:
$1.95
$2.14
52週間の値動き範囲:
$1.60
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
名前
Black Diamond Therapeutics Inc
セクター
電話
617-417-5868
住所
245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA
Compare BDTX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.05 | 116.06M | 70.00M | -43.21M | -34.03M | -0.7579 |
VRTX
Vertex Pharmaceuticals Inc
|
515.55 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.93 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
987.84 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.00 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.51 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2025-11-18 | 再開されました | Piper Sandler | Overweight |
| 2025-10-16 | 再開されました | Stifel | Buy |
| 2025-09-04 | 開始されました | Guggenheim | Buy |
| 2025-07-01 | 再開されました | Raymond James | Outperform |
| 2024-07-31 | 開始されました | Raymond James | Outperform |
| 2023-07-14 | 開始されました | Piper Sandler | Overweight |
| 2023-06-30 | アップグレード | Stifel | Hold → Buy |
| 2023-06-28 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | アップグレード | Wedbush | Neutral → Outperform |
| 2022-03-29 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-03-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | 開始されました | Stifel | Hold |
| 2021-01-07 | 開始されました | Wedbush | Outperform |
| 2020-11-24 | 開始されました | Berenberg | Buy |
| 2020-05-04 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | Canaccord Genuity | Buy |
| 2020-02-24 | 開始されました | Cowen | Outperform |
| 2020-02-24 | 開始されました | JP Morgan | Overweight |
| 2020-02-24 | 開始されました | Jefferies | Buy |
すべてを表示
Black Diamond Therapeutics Inc (BDTX) 最新ニュース
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Black Diamond Therapeutics Stock Price Forecast. Should You Buy BDTX? - StockInvest.us
Black Diamond Settles HMI Cancer-Drug Discovery Patent Lawsuit - news.bloomberglaw.com
Weekly Recap: Silevertinib NSCLC Phase 2 efficacy and $110.5M cash runway - TradingView
Renaissance Technologies LLC Has $3.50 Million Stock Holdings in Black Diamond Therapeutics, Inc. $BDTX - MarketBeat
Black Diamond Therapeutics Inc (BDTX) Stock News Today - TradingKey
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $14 - Moomoo
Black Diamond Therapeutics Inc (BDTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Q1 Earnings Forecast for BDTX Issued By HC Wainwright - MarketBeat
A Quick Look at Today's Ratings for Black Diamond Therapeutics(BDTX.US), With a Forecast Between $8 to $11 - Moomoo
Raymond James Reaffirms Outperform on BDTX Amid Promising NSCLC Trial Data - GuruFocus
Jefferies Optimistic on BDTX Ahead of Q4 Catalysts; Shares Trade Near 1-Year Low - GuruFocus
Piper Sandler Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating, Maintains Target Price $8 - Moomoo
TD Cowen Maintains Black Diamond Therapeutics(BDTX.US) With Buy Rating - Moomoo
Black Diamond Therapeutics (NASDAQ:BDTX) Posts Earnings Results - MarketBeat
Black Diamond Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Black Diamond Therapeutics reports Q2 2026: $110.5M cash, $9.9M net loss - TradingView
Black Diamond Therapeutics, Inc. 2Q 2026: Revenue $0 Net income ($9.91M), EPS ($0.17) — 10-Q Summary - TradingView
Black Diamond Therapeutics Q2 net loss narrows year over year - TradingView
BDTX: Silevertinib demonstrated robust Phase 2 efficacy in NSCLC, supporting pivotal development plans - TradingView
Black Diamond Therapeutics (NASDAQ: BDTX) details Q2 loss and 2028 cash runway - Stock Titan
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
Black Diamond Therapeutics Q2 net loss narrows to $9.91 million; revenue remains no revenue - Bitget
BDTX Q2'26 Earnings: EPS estimate is (0.20) USD - TradingView
Black Diamond Therapeutics Inc expected to post a loss of 20 cents a shareEarnings Preview - TradingView
Black Diamond Therapeutics Inc (BDTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Black Diamond Therapeutics (BDTX) Expected to Post Earnings on Thursday - MarketBeat
BDTX|Black Diamond Therapeutics Inc|Price:1.730|Chg%:-0.030 - TradingKey
Black Diamond Therapeutics (BDTX): BlackRock discloses 3.84M-share, 6.7% ownership - Stock Titan
Black Diamond Therapeutics Inc (BDTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Black Diamond Therapeutics, Inc. Revenue Breakdown – NASDAQ:BDTX - TradingView
Black Diamond Therapeutics Inc (BDTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.760|Chg%:-0.080 - TradingKey
BDTX|Black Diamond Therapeutics Inc|Price:1.770|Chg%:+0.040 - TradingKey
Black Diamond Therapeutics Inc (BDTX) Balance Sheet - TradingKey
Black Diamond Therapeutics Inc (BDTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Black Diamond Therapeutics Inc (BDTX) Cash Flow - TradingKey
TradingKey - TradingKey
Black Diamond Therapeutics Inc (BDTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Trading Down 1.1%Here's What Happened - MarketBeat
BLACK DIAMOND THERAPEUTICS I (BDTX) Stock Price & Overview - ChartMill
Black Diamond Therapeutics (BDTX) 24th Annual Needham Virtual Healthcare Conference summary - Quartr
Black Diamond Therapeutics (BDTX) Edges Higher Amid Key Support TestSeasonality Effect - dars.gov.et
BDTX Q1 2026 Earnings: Narrowed Loss Beats Estimates as Development Progress ContinuesConsensus Beat Rate - dars.gov.et
T. Rowe Price (BDTX) lists 4.03M shares, 7.0% stake in amendment - Stock Titan
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside (NASDAQ:BDTX) - Seeking Alpha
BDTX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Companies Like Black Diamond Therapeutics (NASDAQ:BDTX) Are In A Position To Invest In Growth - simplywall.st
BDTX SEC FilingsBlack Diamond Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Black Diamond Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director Behbahani Ali - Moomoo
Black Diamond Therapeutics Inc (BDTX) 財務データ
収益
当期純利益
現金流量
EPS
1.80%
1.77%
大文字化:
|
ボリューム (24 時間):